Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Phase I/II Trial for Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis

NCT01363401 is registered in ClinicalTrials.gov with Corestemchemon, Inc. as lead sponsor.

NCT NCT01363401
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01363401 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Phase I/II Trial for Safety and Efficacy Study of Autologous Bone Marrow Derived Stem Cell Treatment in Amyotrophic Lateral Sclerosis
Lead sponsor
Corestemchemon, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 28, 2011
Completion date
August 31, 2013
Enrollment
72 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

als, amyotrophic lateral sclerosis